Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > Share price taken down
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(256)
•••
Comment by GameChangerBeton May 17, 2021 8:09am
113 Views
Post# 33212760

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Share price taken down
StockingUp21 wrote:

This is exactly my thought. Things does not add up here. 

 

woundedknee wrote:
Are any of these big pharmas even aware that Antibe exists? If so why has there not yet been any indication of colaborations (other than Nuance) at this stage in the game. For example Ventripoint (V.VPT) just recently made a colaboration agreement with GE Healthcare. Ventripoint is still a venture listed company trading at 40 cents give or take. So why the arguement (which I have supported) that we need to uplist to Naz and commence Phase 3 before we see big US pharmas get involved? Is there something that we are not being told? Dan's past record of being upfront and transparent, some would say, is less than stellar. To be clear, I believe in the product, but wonder if this road management has put us on is longer than neccessary.

 

 



Uplisting to Nasdaq, and particularily starting phase lll, these are not necessities for reaching a deal, however, the further along you are in the process, the arguement would be that there is an increase in value, both in terms of real value as well as negotiating power.
And yes, pharmas are well aware of Antibe, from my understanding the contacting efforts should be completed by months end.
A deal can happen at any time. It might be very near or it might still be a while down the road.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities